ClinicalTrials.gg
CompletedNCT04010539Updated May 30, 2024Results posted

A Study Evaluating Efficacy and Safety of Gepotidacin Compared With Ceftriaxone Plus Azithromycin in the Treatment of Uncomplicated Urogenital Gonorrhea

A Phase 3 interventional study of Gepotidacin and Ceftriaxone in Gonorrhea, sponsored by GlaxoSmithKline. Completed at 51 sites in 6 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2024-05-30.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
628
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 98 studies in Gonorrhea with a site in United States — 11 open to participants now, 11 under way, none of them phase 3. Gonorrhea · United States.

Enrollment
26th of 76
628 · median 341
Started
2019
with 9 others
Phase 3
9 of 98
none open now
Registered
69th of 98
by date

Among the 98 studies in Gonorrhea with a site in United States, this one is the 26th largest by enrollment of the 76 interventional ones that give a count, is one of 10 that started in 2019, is one of 9 in phase 3, and was the 69th registered.

Gonorrhea

168 studies on the registry are indexed under Gonorrhea; 32 are open to participants now.

Browse Gonorrhea studies →

Open to participants now

11 of the 98 studies in Gonorrhea with a site in United States are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 18 Gonorrhea studies recruiting now, 11 (61%) set no upper age limit and 6 (33%) stop at 75 or younger; 10 take children under 18; 12 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 98 studies in Gonorrhea with a site in United States, or all of them as a file.
02

Study summary

This is a phase III, randomized, multicenter, open-label study which will be performed to evaluate efficacy and safety of oral Gepotidacin compared to intramuscular (IM) ceftriaxone plus oral azithromycin for the treatment of uncomplicated urogenital infection caused by Neisseria gonorrhoeae (N. gonorrhoeae) in adolescent and adult participants. In this study, participants will be randomly assigned to receive either oral gepotidacin or IM ceftriaxone plus oral azithromycin.

03

Conditions studied

  • Gonorrhea

Browse trials for

Keywords

  • Urogenital Gonorrhea
  • Gepotidacin
  • Neisseria gonorrhoeae
  • Efficacy
  • Phase 3
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must be >=12 years of age at the time of signing the .
  • Participants having body weight of >45 kilogram (kg).
  • Participants having clinical suspicion of a urogenital gonococcal infection with or without pharyngeal and/or rectal gonococcal infection and have one of the following: male participants with purulent yellow, green, or white urethral discharge or female participants with abnormal cervical or vaginal mucopurulent discharge upon physical examination; or a prior positive culture for N. gonorrhoeae from up to 5 days before screening (as long as the participant has not received any treatment for this infection); or a Gram or equivalent stain (urogenital specimens only) positive or presumptive for Gram-negative intracellular diplococci from up to 5 days before screening (as long as the participant has not received any treatment for this infection); or a prior positive nucleic acid amplification test assay for N. gonorrhoeae from up to 7 days before screening (as long as the participant has not received any treatment for this infection).
  • Participants who are willing to avoid anal, oral, and vaginal sexual intercourse or use condoms for all forms of intercourse from the Baseline Visit through the TOC Visit.
  • Male or female participants having his or her original urogenital anatomy at birth.
  • Male participant must agree to use (male condoms) during intercourse from the Baseline Visit through completion of the TOC Visit.
  • Female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least 1 of the following conditions applies: Not a woman of (WOCBP) or WOCBP who agrees to follow the contraceptive guidance (male partners of WOCBP must use a male condom during intercourse) from the Baseline Visit through completion of the TOC Visit.
  • Participants who are capable of giving signed informed consent or assent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) or assent form and in study protocol.

Exclusion criteria

Exclusion Criteria:

  • Male participants with a current diagnosis of epididymitis and/or orchitis at the time of the Baseline Visit.
  • Participant who is suspected or confirmed to have a Chlamydia trachomatis infection and per the investigator's judgement standard-of-care treatment for this infection cannot be safely postponed until the TOC Visit.
  • Participant has a >=40 kilogram per square meter (kg/m\^2) or has a body mass index >=35.0 kg/m\^2 and is experiencing obesity-related health conditions such as high blood pressure or diabetes.
  • Participant has a history of sensitivity to the study treatments, or components thereof, or a history of a drug (including erythromycin and any macrolide or ketolide drug) or other allergy that, in the opinion of the investigator or medical monitor, contraindicates his or her participation.
  • Participant is or has altered immune defenses that may predispose the participant to a higher risk of treatment failure and/or complications.
  • Participants with a known cluster of differentiation 4 (CD4) count of \<200 cells per cubic millimeter (cells/mm\^3).
  • Participant has any of the following: poorly controlled asthma or , acute severe pain, uncontrolled with conventional medical management, active peptic ulcer disease, Parkinson disease, Myasthenia gravis, a history of seizure disorder requiring medications for control or participant has any surgical or medical condition that may interfere with drug absorption, distribution, metabolism, or excretion of the study treatment.
  • Participant has known anuria, oliguria, or severe impairment of renal function ( \<30 milliliter per minute [mL/min] or elevated serum creatinine as determined by the investigator).
  • Participant in the judgment of the investigator, would not be able or willing to comply with the protocol or complete study follow-up.
  • Participant has a serious underlying disease that could be imminently life threatening, or the participant is unlikely to survive for the duration of the study period.
  • Participant has congenital long syndrome or known prolongation of corrected QT interval (QTc).
  • Participant has uncompensated heart failure.
  • Participant has severe left ventricular hypertrophy.
  • Participant has a family history of QT prolongation or sudden death.
  • Participant has a recent history of vasovagal syncope or episodes of symptomatic bradycardia or bradyarrhythmia within the last 12 months.
  • The participant is taking QT-prolonging drugs or drugs known to increase the risk of torsades de pointes (TdP) per the www.crediblemeds.org "Known Risk of TdP" category at the time of his or her Baseline Visit, which cannot be safely discontinued from the Baseline Visit to the TOC Visit; or the participant is taking a strong cytochrome P450 enzyme 3A4 () inhibitor or a strong P-glycoprotein (P-gp) inhibitor.
  • For any participant >=12 to \<18 years, the participant has an abnormal (ECG) reading.
  • The participant has a QTc >450 millisecond (msec) or a QTc >480 msec for participants with bundle-branch block.
  • Participant has a documented or recent history of uncorrected hypokalemia within the past 3 months.
  • Participant has a known history of cholestatic jaundice or hepatic dysfunction associated with prior use of azithromycin.
  • Participant has a known (ALT) value >2 times (ULN).
  • Participant has a known value >1.5 times ULN (isolated bilirubin >1.5 times ULN is acceptable if bilirubin is fractionated and direct bilirubin \<35%).
  • Participant has a current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones), including symptomatic viral hepatitis or moderate-to-severe liver insufficiency ( class B or C).
  • Participant has been previously randomized in this study or has previously been treated with Gepotidacin.
  • Participant has participated in a clinical trial and has received an product within 30 days or 5 half-lives, whichever is longer.
  • Participant has any of the following gonococcal infections that require a different dose or duration of treatment: suspected or confirmed pelvic inflammatory disease; or suspected or confirmed gonococcal arthritis; or suspected or confirmed gonococcal conjunctivitis; or suspected or confirmed gonococcal endocarditis; or other evidence of disseminated gonococcal infection.
  • Participant has received any antibacterial therapy for the treatment of a gonococcal infection within 14 days before the Baseline Visit.
  • Participant has received any systemic, topical, or intravaginal antibiotics or any systemic antifungals within 7 days before the Baseline Visit.
  • Participant must not use St John's wort or ergot derivatives from within 14 days before the Baseline Visit through the TOC Visit.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
628 participants (actual)

Study arms

  • Experimental
    Participants receiving Gepotidacin

    Participants will receive Gepotidacin orally at the study site during the Baseline (Day 1) visit followed by self-administration of a second oral dose as an outpatient 10 to 12 hours after the first dose.

    Drug: Gepotidacin

  • Active comparator
    Participants receiving Ceftriaxone plus Azithromycin

    Participants will receive a single IM dose of Ceftriaxone plus a single oral dose of Azithromycin at the study site during the Baseline (Day 1) visit.

    Drug: Ceftriaxone · Drug: Azithromycin

Interventions

  • Gepotidacin will be administered as 3000 milligram (mg) oral dose (4 X 750 mg tablets) at the study site followed by 3000 mg oral dose (4 X 750 mg tablets) as an outpatient. Each dose should be taken after food consumption and with water.

  • Ceftriaxone is available as sterile powder for reconstitution. It will be administered as one 500-mg IM dose at the study site.

  • Azithromycin will be administered as 1000 mg oral dose (2 X 500 mg tablets) at the study site. Dose should be taken after food consumption and with water.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Culture-Confirmed Bacterial Eradication of Neisseria Gonorrhoeae (NG) From the Urogenital Site at the Test-Of-Cure (TOC) Visit (Day 4 to 8)

    Urogenital specimens were obtained for bacteriological culture at the Baseline (Day 1) and TOC (Day 4 to 8) visits and were compared to determine microbiological outcome. Microbiological success was defined as culture-confirmed elimination of baseline pathogen (NG) from a bacteriology sample taken at the TOC visit without the participant receiving other systemic antimicrobials before this visit. Microbiological failure was categorized as "Bacterial Persistence (BP)" and "Unable to Determine (UTD)" outcomes. Bacterial persistence was defined as culture-confirmed persistence of baseline NG pathogen from a bacteriology sample taken at the TOC visit without the participant receiving other systemic antimicrobials before this visit. UTD was defined as inability to determine the TOC NG pathogen outcome (e.g., no bacteriological sample taken for culture, sample lost, visit did not occur etc.) or the participant received other systemic antimicrobials before the TOC visit.

    Time frame: Baseline (Day 1) and TOC visit (Day 4 to 8)

Secondary outcomes

  1. Number of Participants With Culture-Confirmed Bacterial Eradication of NG From the Rectal Site at the TOC Visit

    Rectal specimens were obtained for bacteriological culture at the Baseline (Day 1) and TOC (Day 4 to 8) visits and were compared to determine microbiological outcome. Microbiological success was defined as culture-confirmed elimination of baseline pathogen (NG) from a bacteriology sample taken at the TOC visit without the participant receiving other systemic antimicrobials before this visit. Microbiological failure was categorized as "Bacterial Persistence (BP)" and "Unable to Determine (UTD)" outcomes. Bacterial persistence was defined as culture-confirmed persistence of baseline NG pathogen from a bacteriology sample taken at the TOC visit without the participant receiving other systemic antimicrobials before this visit. UTD was defined as inability to determine the TOC NG pathogen outcome (e.g., no bacteriological sample taken for culture, sample lost, visit did not occur etc.) or the participant received other systemic antimicrobials before the TOC visit.

    Time frame: Baseline (Day 1) and TOC visit (Day 4 to 8)

  2. Number of Participants With Culture-Confirmed Bacterial Eradication of NG From the Pharyngeal Site at the TOC Visit

    Pharyngeal specimens were obtained for bacteriological culture at the Baseline (Day 1) and TOC (Day 4 to 8) visits and were compared to determine microbiological outcome. Microbiological success was defined as culture-confirmed elimination of baseline pathogen (NG) from a bacteriology sample taken at the TOC visit without the participant receiving other systemic antimicrobials before this visit. Microbiological failure was categorized as "Bacterial Persistence (BP)" and "Unable to Determine (UTD)" outcomes. Bacterial persistence was defined as culture-confirmed persistence of baseline NG pathogen from a bacteriology sample taken at the TOC visit without the participant receiving other systemic antimicrobials before this visit. UTD was defined as inability to determine the TOC NG pathogen outcome (e.g., no bacteriological sample taken for culture, sample lost, visit did not occur etc.) or the participant received other systemic antimicrobials before the TOC visit.

    Time frame: Baseline (Day 1) and TOC visit (Day 4 to 8)

  3. Number of Participants With Any Treatment-emergent Adverse Events (TEAEs) and Any Serious Adverse Events (SAEs)

    An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A TEAE is an event that emerges during treatment having been absent pretreatment or worsens relative to the pretreatment state. An SAE is defined as any untoward medical occurrence that, at any dose, results in death; was life threatening; required hospitalization or prolongation of existing hospitalization; resulted in disability/incapacity; was a congenital anomaly/birth defect.

    Time frame: Up to 21 days

  4. Change From Baseline (CFB) in Hematology Parameters: Basophils, Eosinophil, Leukocytes, Neutrophils, Platelets, Lymphocytes, Monocytes, Neutrophils and Nucleated Erythrocytes

    Blood samples were collected for the assessment of change from baseline in hematology parameters: basophils, eosinophil, leukocytes, neutrophils, platelets, lymphocytes, monocytes, neutrophils and nucleated erythrocytes. Baseline (Day 1) was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.

    Time frame: Baseline (Day 1) and TOC visit (Day 4 to 8)

  5. Change From Baseline in Hematology Parameters: Mean Corpuscular Hemoglobin Concentration (MCHC) and Hemoglobin (Hb)

    Blood samples were collected for the assessment of change from baseline in hematology parameters: mean corpuscular hemoglobin concentration and hemoglobin. Baseline (Day 1) was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.

    Time frame: Baseline (Day 1) and TOC visit (Day 4 to 8)

  6. Change From Baseline in Hematology Parameter: Hematocrit

    Blood samples were collected for the assessment of change from baseline in hematology parameter: hematocrit. Baseline (Day 1) was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.

    Time frame: Baseline (Day 1) and TOC visit (Day 4 to 8)

  7. Change From Baseline in Hematology Parameter: Erythrocytes

    Blood samples were collected for the assessment of change from baseline in hematology parameter: red blood cell (RBC) count. Baseline (Day 1) was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.

    Time frame: Baseline (Day 1) and TOC visit (Day 4 to 8)

  8. Change From Baseline in Hematology Parameter: Mean Corpuscular Hemoglobin (MCH)

    Blood samples were collected for the assessment of change from baseline in hematology parameter: mean corpuscular hemoglobin (MCH). Baseline (Day 1) was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.

    Time frame: Baseline (Day 1) and TOC visit (Day 4 to 8)

  9. Change From Baseline in Hematology Parameter: Mean Corpuscular Volume (MCV)

    Blood samples were collected for the assessment of change from baseline in hematology parameter: mean corpuscular volume (MCV). Baseline (Day 1) was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.

    Time frame: Baseline (Day 1) and TOC visit (Day 4 to 8)

  10. Change From Baseline in Clinical Chemistry Parameters: Urea Nitrogen (UN), Glucose, Calcium, Chloride, Sodium, Magnesium and Potassium

    Blood samples were collected for the assessment of change from baseline in clinincal chemistry parameters: urea nitrogen (UN), glucose, calcium, chloride, sodium, magnesium and potassium. Baseline (Day 1) was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.

    Time frame: Baseline (Day 1) and TOC visit (Day 4 to 8)

  11. Change From Baseline in Clinical Chemistry Parameters: Bilirubin, Direct Bilirubin and Creatinine

    Blood samples were collected for the assessment of change from baseline in clinical chemistry parameters: bilirubin, direct bilirubin and creatinine levels. Baseline (Day 1) was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.

    Time frame: Baseline (Day 1) and TOC visit (Day 4 to 8)

  12. Change From Baseline in Clinical Chemistry Parameters: Albumin and Protein

    Blood samples were collected for the assessment of change from baseline in clinical chemistry parameters: albumin and protein. Baseline (Day 1) was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.

    Time frame: Baseline (Day 1) and TOC visit (Day 4 to 8)

  13. Change From Baseline in Clinical Chemistry Parameters: Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) and Alkaline Phosphatase (ALP)

    Blood samples were collected for the assessment of change from baseline in clinincal chemistry parameters: aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase (ALP). Baseline (Day 1) was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.

    Time frame: Baseline (Day 1) and TOC visit (Day 4 to 8)

  14. Number of Participants With Urinalysis Dipstick Results

    Urine samples were collected for urinalysis: Glucose, Protein, Occult Blood and Ketones. The dipstick test gives results in a semi-quantitative manner, and results can be read as Negative, Small, Moderate, Large, Positive, 5 milligram per deciliter (mg/dL), 20 mg/dL, 30 mg/dL 50 mg/dL, 100 mg/dL, 150 mg/dL and \>=500 mg/dL indicating concentrations in the urine sample. In the row title (Glucose, Baseline, Negative), Glucose indicates parameter, Baseline is the visit and Negative indicates the concentration in the urine sample. Baseline (Day 1) was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.

    Time frame: Baseline (Day 1) and TOC visit (Day 4 to 8)

  15. Absolute Values in Specific Gravity of Urine

    Urine samples were collected from participants to assess urine specific gravity. Baseline (Day 1) was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.

    Time frame: Baseline (Day 1) and TOC visit (Day 4 to 8)

  16. Absolute Values in Potential of Hydrogen (pH) of Urine

    Urine samples were collected from participants to assess urine pH. Baseline (Day 1) was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.

    Time frame: Baseline (Day 1) and TOC visit (Day 4 to 8)

  17. Change From Baseline in Vital Signs: Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)

    SBP and DBP were measured in a semi-supine position after 5 minutes rest. Baseline (Day 1) is the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.

    Time frame: Baseline (Day 1) and TOC visit (Day 4 to 8)

  18. Change From Baseline in Vital Sign: Pulse Rate

    Pulse rate was measured in a semi-supine position after 5 minutes rest. Baseline (Day 1) is the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.

    Time frame: Baseline (Day 1) and TOC visit (Day 4 to 8)

  19. Change From Baseline in Vital Sign: Temperature

    Temperature was measured after 5 minutes rest. Baseline (Day 1) is the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.

    Time frame: Baseline (Day 1) and TOC visit (Day 4 to 8)

07

Results

Posted May 30, 2024

Participant flow

Participant flow — Overall Study
MilestoneGepotidacinCeftriaxone Plus Azithromycin
Started314314
Safety population309313
Microbiological itt (micro-itt) population202204
Micro-itt rectal population2615
Micro-itt pharyngeal population1817
Completed294295
Not completed2019
Withdrew: Withdrawal by subject41
Withdrew: Physician decision02
Withdrew: Lost to follow-up1014
Withdrew: Adverse event30
Withdrew: Participant did not receive ip01
Withdrew: Protocol deviation01
Withdrew: Randomized in error/ mistake20
Withdrew: Eligibility criteria unable to evaluate10

Outcome measures

PrimaryNumber of Participants With Culture-Confirmed Bacterial Eradication of Neisseria Gonorrhoeae (NG) From the Urogenital Site at the Test-Of-Cure (TOC) Visit (Day 4 to 8)

Urogenital specimens were obtained for bacteriological culture at the Baseline (Day 1) and TOC (Day 4 to 8) visits and were compared to determine microbiological outcome. Microbiological success was defined as culture-confirmed elimination of baseline pathogen (NG) from a bacteriology sample taken at the TOC visit without the participant receiving other systemic antimicrobials before this visit. Microbiological failure was categorized as "Bacterial Persistence (BP)" and "Unable to Determine (UTD)" outcomes. Bacterial persistence was defined as culture-confirmed persistence of baseline NG pathogen from a bacteriology sample taken at the TOC visit without the participant receiving other systemic antimicrobials before this visit. UTD was defined as inability to determine the TOC NG pathogen outcome (e.g., no bacteriological sample taken for culture, sample lost, visit did not occur etc.) or the participant received other systemic antimicrobials before the TOC visit.

Time frame:
Baseline (Day 1) and TOC visit (Day 4 to 8)
Reported as:
Count of participants · Participants
Number of Participants With Culture-Confirmed Bacterial Eradication of Neisseria Gonorrhoeae (NG) From the Urogenital Site at the Test-Of-Cure (TOC) Visit (Day 4 to 8)
ParticipantsGepotidacinCeftriaxone Plus Azithromycin
Microbiological success187186
Microbiological failure, BP00
Microbiological failure, UTD1518
Statistical analysis
  • Gepotidacin vs Ceftriaxone Plus Azithromycin · Adjusted difference in percent: -0.1 · 95% CI -5.6 to 5.5
  • Gepotidacin vs Ceftriaxone Plus Azithromycin · 1-sided p-value for Test of Superiority · p = 0.5072 · Adjusted difference in percent: -0.1 · 95% CI -5.6 to 5.5
SecondaryNumber of Participants With Culture-Confirmed Bacterial Eradication of NG From the Rectal Site at the TOC Visit

Rectal specimens were obtained for bacteriological culture at the Baseline (Day 1) and TOC (Day 4 to 8) visits and were compared to determine microbiological outcome. Microbiological success was defined as culture-confirmed elimination of baseline pathogen (NG) from a bacteriology sample taken at the TOC visit without the participant receiving other systemic antimicrobials before this visit. Microbiological failure was categorized as "Bacterial Persistence (BP)" and "Unable to Determine (UTD)" outcomes. Bacterial persistence was defined as culture-confirmed persistence of baseline NG pathogen from a bacteriology sample taken at the TOC visit without the participant receiving other systemic antimicrobials before this visit. UTD was defined as inability to determine the TOC NG pathogen outcome (e.g., no bacteriological sample taken for culture, sample lost, visit did not occur etc.) or the participant received other systemic antimicrobials before the TOC visit.

Time frame:
Baseline (Day 1) and TOC visit (Day 4 to 8)
Reported as:
Count of participants · Participants
Number of Participants With Culture-Confirmed Bacterial Eradication of NG From the Rectal Site at the TOC Visit
ParticipantsGepotidacinCeftriaxone Plus Azithromycin
Microbiological success2612
Microbiological failure, BP00
Microbiological failure, UTD03
SecondaryNumber of Participants With Culture-Confirmed Bacterial Eradication of NG From the Pharyngeal Site at the TOC Visit

Pharyngeal specimens were obtained for bacteriological culture at the Baseline (Day 1) and TOC (Day 4 to 8) visits and were compared to determine microbiological outcome. Microbiological success was defined as culture-confirmed elimination of baseline pathogen (NG) from a bacteriology sample taken at the TOC visit without the participant receiving other systemic antimicrobials before this visit. Microbiological failure was categorized as "Bacterial Persistence (BP)" and "Unable to Determine (UTD)" outcomes. Bacterial persistence was defined as culture-confirmed persistence of baseline NG pathogen from a bacteriology sample taken at the TOC visit without the participant receiving other systemic antimicrobials before this visit. UTD was defined as inability to determine the TOC NG pathogen outcome (e.g., no bacteriological sample taken for culture, sample lost, visit did not occur etc.) or the participant received other systemic antimicrobials before the TOC visit.

Time frame:
Baseline (Day 1) and TOC visit (Day 4 to 8)
Reported as:
Count of participants · Participants
Number of Participants With Culture-Confirmed Bacterial Eradication of NG From the Pharyngeal Site at the TOC Visit
ParticipantsGepotidacinCeftriaxone Plus Azithromycin
Microbiological success1416
Microbiological failure, BP20
Microbiological failure, UTD21
SecondaryNumber of Participants With Any Treatment-emergent Adverse Events (TEAEs) and Any Serious Adverse Events (SAEs)

An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A TEAE is an event that emerges during treatment having been absent pretreatment or worsens relative to the pretreatment state. An SAE is defined as any untoward medical occurrence that, at any dose, results in death; was life threatening; required hospitalization or prolongation of existing hospitalization; resulted in disability/incapacity; was a congenital anomaly/birth defect.

Time frame:
Up to 21 days
Reported as:
Count of participants · Participants
Number of Participants With Any Treatment-emergent Adverse Events (TEAEs) and Any Serious Adverse Events (SAEs)
ParticipantsGepotidacinCeftriaxone Plus Azithromycin
Any TEAEs230104
Any SAEs10
SecondaryChange From Baseline (CFB) in Hematology Parameters: Basophils, Eosinophil, Leukocytes, Neutrophils, Platelets, Lymphocytes, Monocytes, Neutrophils and Nucleated Erythrocytes

Blood samples were collected for the assessment of change from baseline in hematology parameters: basophils, eosinophil, leukocytes, neutrophils, platelets, lymphocytes, monocytes, neutrophils and nucleated erythrocytes. Baseline (Day 1) was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.

Time frame:
Baseline (Day 1) and TOC visit (Day 4 to 8)
Reported as:
Mean · Giga cells per liter (10^9 cells/L)
Change From Baseline (CFB) in Hematology Parameters: Basophils, Eosinophil, Leukocytes, Neutrophils, Platelets, Lymphocytes, Monocytes, Neutrophils and Nucleated Erythrocytes
Giga cells per liter (10^9 cells/L)GepotidacinCeftriaxone Plus Azithromycin
Basophils, Baseline (Day 1)0.044 ± 0.01960.045 ± 0.0222
Basophils, CFB to TOC0.001 ± 0.01670.000 ± 0.0152
Eosinophils, Baseline (Day 1)0.154 ± 0.21170.160 ± 0.1384
Eosinophils, CFB to TOC0.009 ± 0.12890.018 ± 0.0827
Leukocytes, Baseline (Day 1)7.143 ± 2.28087.507 ± 2.2045
Leukocytes, CFB to TOC-0.811 ± 1.8536-1.267 ± 1.9362
Neutrophils, Baseline (Day 1)4.443 ± 1.96214.774 ± 1.9355
Neutrophils, CFB to TOC-1.062 ± 1.7309-1.473 ± 1.8860
Platelets, Baseline (Day 1)260.3 ± 61.79268.4 ± 69.26
Platelets, CFB to TOC10.2 ± 32.149.7 ± 34.94
Lymphocytes, Baseline (Day 1)1.934 ± 0.59411.948 ± 0.6321
Lymphocytes, CFB to TOC0.277 ± 0.52050.245 ± 0.5511
Monocytes, Baseline (Day 1)0.559 ± 0.22090.572 ± 0.1877
Monocytes, CFB to TOC-0.034 ± 0.1917-0.053 ± 0.1782
Nucleated Erythrocytes, Baseline (Day 1)0.002 ± 0.00470.001 ± 0.0038
Nucleated Erythrocytes, CFB to TOC0.000 ± 0.00700.001 ± 0.0059
SecondaryChange From Baseline in Hematology Parameters: Mean Corpuscular Hemoglobin Concentration (MCHC) and Hemoglobin (Hb)

Blood samples were collected for the assessment of change from baseline in hematology parameters: mean corpuscular hemoglobin concentration and hemoglobin. Baseline (Day 1) was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.

Time frame:
Baseline (Day 1) and TOC visit (Day 4 to 8)
Reported as:
Mean · Grams per liter (g/L)
Change From Baseline in Hematology Parameters: Mean Corpuscular Hemoglobin Concentration (MCHC) and Hemoglobin (Hb)
Grams per liter (g/L)GepotidacinCeftriaxone Plus Azithromycin
MCHC, Baseline (Day 1)318.5 ± 16.27318.8 ± 16.12
MCHC, CFB to TOC2.4 ± 10.670.3 ± 11.27
Hb, Baseline (Day 1)149.1 ± 12.83149.2 ± 12.58
Hb, CFB to TOC0.00 ± 6.700.6 ± 6.92
SecondaryChange From Baseline in Hematology Parameter: Hematocrit

Blood samples were collected for the assessment of change from baseline in hematology parameter: hematocrit. Baseline (Day 1) was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.

Time frame:
Baseline (Day 1) and TOC visit (Day 4 to 8)
Reported as:
Mean · Percentage
Change From Baseline in Hematology Parameter: Hematocrit
PercentageGepotidacinCeftriaxone Plus Azithromycin
Baseline (Day 1)0.4691 ± 0.042050.4687 ± 0.04104
CFB to TOC-0.0038 ± 0.025260.0012 ± 0.02666
SecondaryChange From Baseline in Hematology Parameter: Erythrocytes

Blood samples were collected for the assessment of change from baseline in hematology parameter: red blood cell (RBC) count. Baseline (Day 1) was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.

Time frame:
Baseline (Day 1) and TOC visit (Day 4 to 8)
Reported as:
Mean · Trillion cells per liter (10^12 cells/L)
Change From Baseline in Hematology Parameter: Erythrocytes
Trillion cells per liter (10^12 cells/L)GepotidacinCeftriaxone Plus Azithromycin
Baseline (Day 1)4.911 ± 0.47224.926 ± 0.4601
CFB to TOC0.003 ± 0.22610.019 ± 0.2332
SecondaryChange From Baseline in Hematology Parameter: Mean Corpuscular Hemoglobin (MCH)

Blood samples were collected for the assessment of change from baseline in hematology parameter: mean corpuscular hemoglobin (MCH). Baseline (Day 1) was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.

Time frame:
Baseline (Day 1) and TOC visit (Day 4 to 8)
Reported as:
Mean · Picograms (pg)
Change From Baseline in Hematology Parameter: Mean Corpuscular Hemoglobin (MCH)
Picograms (pg)GepotidacinCeftriaxone Plus Azithromycin
Baseline (Day 1)30.46 ± 1.97830.38 ± 1.987
CFB to TOC-0.03 ± 0.4510.00 ± 0.594
SecondaryChange From Baseline in Hematology Parameter: Mean Corpuscular Volume (MCV)

Blood samples were collected for the assessment of change from baseline in hematology parameter: mean corpuscular volume (MCV). Baseline (Day 1) was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.

Time frame:
Baseline (Day 1) and TOC visit (Day 4 to 8)
Reported as:
Mean · Femtoliters (fL)
Change From Baseline in Hematology Parameter: Mean Corpuscular Volume (MCV)
Femtoliters (fL)GepotidacinCeftriaxone Plus Azithromycin
Baseline (Day 1)95.79 ± 6.26695.43 ± 6.760
CFB to TOC-0.85 ± 3.104-0.12 ± 3.084
SecondaryChange From Baseline in Clinical Chemistry Parameters: Urea Nitrogen (UN), Glucose, Calcium, Chloride, Sodium, Magnesium and Potassium

Blood samples were collected for the assessment of change from baseline in clinincal chemistry parameters: urea nitrogen (UN), glucose, calcium, chloride, sodium, magnesium and potassium. Baseline (Day 1) was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.

Time frame:
Baseline (Day 1) and TOC visit (Day 4 to 8)
Reported as:
Mean · Millimoles per liter (mmol/L)
Change From Baseline in Clinical Chemistry Parameters: Urea Nitrogen (UN), Glucose, Calcium, Chloride, Sodium, Magnesium and Potassium
Millimoles per liter (mmol/L)GepotidacinCeftriaxone Plus Azithromycin
UN, Baseline (Day 1)4.793 ± 1.42934.800 ± 1.4669
UN, CFB to TOC0.190 ± 1.16400.282 ± 1.1920
Glucose, Baseline5.049 ± 1.05575.090 ± 1.1183
Glucose, CFB to TOC0.227 ± 0.94250.064 ± 0.9684
Calcium, Baseline (Day 1)2.387 ± 0.09862.387 ± 0.0954
Calcium, CFB to TOC-0.009 ± 0.0852-0.015 ± 0.0871
Chloride, Baseline (Day 1)101.7 ± 2.26101.7 ± 2.30
Chloride, CFB to TOC0.7 ± 2.570.5 ± 2.40
Sodium, Baseline (Day 1)139.6 ± 2.11139.6 ± 2.02
Sodium, CFB to TOC0.2 ± 2.190.1 ± 2.44
Magnesium, Baseline (Day 1)0.854 ± 0.06120.855 ± 0.0637
Magnesium, CFB to TOC-0.003 ± 0.0604-0.004 ± 0.0584
Potassium, Baseline (Day 1)4.29 ± 0.3234.30 ± 0.332
Potassium, CFB to TOC-0.04 ± 0.336-0.03 ± 0.345
SecondaryChange From Baseline in Clinical Chemistry Parameters: Bilirubin, Direct Bilirubin and Creatinine

Blood samples were collected for the assessment of change from baseline in clinical chemistry parameters: bilirubin, direct bilirubin and creatinine levels. Baseline (Day 1) was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.

Time frame:
Baseline (Day 1) and TOC visit (Day 4 to 8)
Reported as:
Mean · Micromoles per liter (umol/L)
Change From Baseline in Clinical Chemistry Parameters: Bilirubin, Direct Bilirubin and Creatinine
Micromoles per liter (umol/L)GepotidacinCeftriaxone Plus Azithromycin
Bilirubin, Baseline (Day 1)8.54 ± 5.8617.71 ± 4.806
Bilirubin, CFB to TOC-0.05 ± 5.025-0.14 ± 3.914
Direct Bilirubin, Baseline (Day 1)3.83 ± 1.2483.76 ± 1.210
Direct Bilirubin, CFB to TOC-0.02 ± 0.8970.01 ± 0.876
Creatinine, Baseline (Day 1)75.9 ± 34.1275.0 ± 20.63
Creatinine, CFB to TOC-0.2 ± 34.082.6 ± 9.52
SecondaryChange From Baseline in Clinical Chemistry Parameters: Albumin and Protein

Blood samples were collected for the assessment of change from baseline in clinical chemistry parameters: albumin and protein. Baseline (Day 1) was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.

Time frame:
Baseline (Day 1) and TOC visit (Day 4 to 8)
Reported as:
Mean · Grams per liter (g/L)
Change From Baseline in Clinical Chemistry Parameters: Albumin and Protein
Grams per liter (g/L)GepotidacinCeftriaxone Plus Azithromycin
Albumin, Baseline (Day 1)46.9 ± 3.1246.8 ± 3.19
Albumin, CFB to TOC-0.3 ± 2.35-0.3 ± 2.67
Protein, Baseline (Day 1)73.1 ± 4.8073.3 ± 4.85
Protein, CFB to TOC-0.5 ± 3.86-0.5 ± 4.02
SecondaryChange From Baseline in Clinical Chemistry Parameters: Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) and Alkaline Phosphatase (ALP)

Blood samples were collected for the assessment of change from baseline in clinincal chemistry parameters: aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase (ALP). Baseline (Day 1) was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.

Time frame:
Baseline (Day 1) and TOC visit (Day 4 to 8)
Reported as:
Mean · International units per Liter (IU/L)
Change From Baseline in Clinical Chemistry Parameters: Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) and Alkaline Phosphatase (ALP)
International units per Liter (IU/L)GepotidacinCeftriaxone Plus Azithromycin
AST, Baseline (Day 1)24.4 ± 15.3024.2 ± 16.29
AST, CFB to TOC2.8 ± 19.510.9 ± 13.25
ALT, Baseline (Day 1)23.7 ± 18.7823.7 ± 14.35
ALT, CFB to TOC1.4 ± 12.591.1 ± 7.64
ALP, Baseline (Day 1)76.0 ± 20.8677.1 ± 26.53
ALP, CFB to TOC-0.4 ± 7.73-1.5 ± 7.80
SecondaryNumber of Participants With Urinalysis Dipstick Results

Urine samples were collected for urinalysis: Glucose, Protein, Occult Blood and Ketones. The dipstick test gives results in a semi-quantitative manner, and results can be read as Negative, Small, Moderate, Large, Positive, 5 milligram per deciliter (mg/dL), 20 mg/dL, 30 mg/dL 50 mg/dL, 100 mg/dL, 150 mg/dL and \>=500 mg/dL indicating concentrations in the urine sample. In the row title (Glucose, Baseline, Negative), Glucose indicates parameter, Baseline is the visit and Negative indicates the concentration in the urine sample. Baseline (Day 1) was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.

Time frame:
Baseline (Day 1) and TOC visit (Day 4 to 8)
Reported as:
Count of participants · Participants
Number of Participants With Urinalysis Dipstick Results
ParticipantsGepotidacinCeftriaxone Plus Azithromycin
Glucose, Baseline (Day 1), Negative296305
Glucose, Baseline (Day 1), 150 mg/dL00
Glucose, Baseline (Day 1), >=500 mg/dL32
Glucose, TOC, Negative284283
Glucose, TOC, 150 mg/dL11
Glucose, TOC, >=500 mg/dL21
Ketones, Baseline (Day 1), Negative288300
Ketones, Baseline (Day 1), 5 mg/dL107
Ketones, Baseline (Day 1), 20 mg/dL10
Ketones, TOC, Negative279279
Ketones, TOC, 5 mg/dL76
Ketones, TOC, 20 mg/dL10
Occult Blood, Baseline (Day 1), Negative202192
Occult Blood, Baseline (Day 1), Small7791
Occult Blood, Baseline (Day 1), Moderate1819
Occult Blood, Baseline (Day 1), Large25
Occult Blood, TOC, Negative251252
Occult Blood, TOC, Small3024
Occult Blood, TOC, Moderate36
Occult Blood, TOC, Large33
Protein, Baseline (Day 1), Negative212210
Protein, Baseline (Day 1), 30 mg/dL7983
Protein, Baseline (Day 1), 100 mg/dL813
Protein, Baseline (Day 1), >=500 mg/dL01
Protein, TOC, Negative239244
Protein, TOC, 30 mg/dL4637
Protein, TOC, 100 mg/dL24
Protein, TOC, >=500 mg/dL00
SecondaryAbsolute Values in Specific Gravity of Urine

Urine samples were collected from participants to assess urine specific gravity. Baseline (Day 1) was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.

Time frame:
Baseline (Day 1) and TOC visit (Day 4 to 8)
Reported as:
Mean · Ratio
Absolute Values in Specific Gravity of Urine
RatioGepotidacinCeftriaxone Plus Azithromycin
Baseline (Day 1)1.0211 ± 0.007501.0207 ± 0.00747
TOC1.0211 ± 0.007201.0216 ± 0.00748
SecondaryAbsolute Values in Potential of Hydrogen (pH) of Urine

Urine samples were collected from participants to assess urine pH. Baseline (Day 1) was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.

Time frame:
Baseline (Day 1) and TOC visit (Day 4 to 8)
Reported as:
Mean · pH
Absolute Values in Potential of Hydrogen (pH) of Urine
pHGepotidacinCeftriaxone Plus Azithromycin
Baseline (Day 1)5.6 ± 0.695.6 ± 0.70
TOC5.5 ± 0.645.4 ± 0.62
SecondaryChange From Baseline in Vital Signs: Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)

SBP and DBP were measured in a semi-supine position after 5 minutes rest. Baseline (Day 1) is the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.

Time frame:
Baseline (Day 1) and TOC visit (Day 4 to 8)
Reported as:
Mean · Millimeters of mercury (mmHg)
Change From Baseline in Vital Signs: Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
Millimeters of mercury (mmHg)GepotidacinCeftriaxone Plus Azithromycin
SBP, Baseline (Day 1)123.9 ± 13.69125.1 ± 14.41
SBP, CFB to TOC-0.4 ± 12.61-0.5 ± 12.86
DBP, Baseline (Day 1)76.7 ± 10.7777.2 ± 10.50
DBP, CFB to TOC0.1 ± 9.10-0.9 ± 9.54
SecondaryChange From Baseline in Vital Sign: Pulse Rate

Pulse rate was measured in a semi-supine position after 5 minutes rest. Baseline (Day 1) is the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.

Time frame:
Baseline (Day 1) and TOC visit (Day 4 to 8)
Reported as:
Mean · Beats per minute
Change From Baseline in Vital Sign: Pulse Rate
Beats per minuteGepotidacinCeftriaxone Plus Azithromycin
Baseline (Day 1)73.0 ± 12.2472.8 ± 12.20
CFB to TOC2.2 ± 12.442.4 ± 12.33
SecondaryChange From Baseline in Vital Sign: Temperature

Temperature was measured after 5 minutes rest. Baseline (Day 1) is the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.

Time frame:
Baseline (Day 1) and TOC visit (Day 4 to 8)
Reported as:
Mean · Celsius (C)
Change From Baseline in Vital Sign: Temperature
Celsius (C)GepotidacinCeftriaxone Plus Azithromycin
Baseline (Day 1)36.45 ± 0.39536.44 ± 0.457
CFB to TOC-0.03 ± 0.381-0.06 ± 0.485

Adverse events

Collected over All cause mortality, non-serious adverse events (Non-SAEs) and serious adverse events (SAEs) were collected from Day 1 through the final follow-up visit (up to 21Days).. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Gepotidacin0/309 (0%)1/309 (0.3%)230/309 (74.4%)
Ceftriaxone Plus Azithromycin0/313 (0%)0/313 (0%)81/313 (25.9%)
Most frequent serious events
Most frequent serious events
EventGepotidacinCeftriaxone Plus Azithromycin
Lower limb fractureInjury, poisoning and procedural complications1/3090/313
Most frequent other events
Showing 10 of 19
Most frequent other events
EventGepotidacinCeftriaxone Plus Azithromycin
DiarrhoeaGastrointestinal disorders151/30930/313
NauseaGastrointestinal disorders73/3099/313
VomitingGastrointestinal disorders20/3092/313
FlatulenceGastrointestinal disorders20/3091/313
Abdominal PainGastrointestinal disorders16/3093/313
Faeces softGastrointestinal disorders16/3091/313
DizzinessNervous system disorders16/3092/313
Chlamydial infectionInfections and infestations12/30910/313
HeadacheNervous system disorders10/3098/313
FatigueGeneral disorders8/3090/313

Baseline characteristics

Age, Continuous
Age, Continuous(Years)GepotidacinCeftriaxone Plus AzithromycinTotal
Mean33.9 ± 10.4233.7 ± 10.7033.8 ± 10.56
Sex: Female, Male
Sex: Female, Male(Participants)GepotidacinCeftriaxone Plus AzithromycinTotal
Female353469
Male279280559
Race (NIH/OMB)
Race (NIH/OMB)(Participants)GepotidacinCeftriaxone Plus AzithromycinTotal
American Indian or Alaska Native91019
Asian121729
Native Hawaiian or Other Pacific Islander729
Black or African American493988
White231241472
More than one race6511
Unknown or Not Reported000
08

Study locations

51 sites
  • GSK Investigational Site
    Los Angeles, California 90036, United States
  • GSK Investigational Site
    Palm Springs, California 92262, United States
  • GSK Investigational Site
    DeLand, Florida 32720, United States
  • GSK Investigational Site
    Orlando, Florida 32803, United States
  • GSK Investigational Site
    Decatur, Georgia 30033, United States
  • GSK Investigational Site
    Indianapolis, Indiana 46202, United States
  • GSK Investigational Site
    New Orleans, Louisiana 70119, United States
  • GSK Investigational Site
    Springfield, Massachusetts 01105, United States
  • GSK Investigational Site
    Fayetteville, North Carolina 28303-5537, United States
  • GSK Investigational Site
    Greensboro, North Carolina 27405, United States
  • GSK Investigational Site
    Cleveland, Ohio 44109, United States
  • GSK Investigational Site
    Houston, Texas 77098, United States
  • GSK Investigational Site
    Longview, Texas 75602, United States
  • GSK Investigational Site
    Darlinghurst, Sydney, New South Wales 2010, Australia
  • GSK Investigational Site
    Darlinghurst, New South Wales 2010, Australia
  • GSK Investigational Site
    Southport, Queensland 4215, Australia
  • GSK Investigational Site
    Carlton, Victoria 3053, Australia
  • GSK Investigational Site
    Prahran, Victoria 3181, Australia
  • GSK Investigational Site
    Muenchen, Bayern 81675, Germany
  • GSK Investigational Site
    Frankfurt, Hessen 60590, Germany
  • GSK Investigational Site
    Frankfurt, Hessen 60596, Germany
  • GSK Investigational Site
    Koeln, Nordrhein-Westfalen 50924, Germany
  • GSK Investigational Site
    Berlin, 10243, Germany
  • GSK Investigational Site
    Berlin, 10439, Germany
  • GSK Investigational Site
    Hamburg, 20146, Germany
  • GSK Investigational Site
    München, 80336, Germany
  • GSK Investigational Site
    Guadalajara, Jalisco 44160, Mexico
  • GSK Investigational Site
    Guadalajara, Jalisco 44280, Mexico
  • GSK Investigational Site
    Monterrey, 64460, Mexico
  • GSK Investigational Site
    Barcelona, 08036, Spain
  • GSK Investigational Site
    Barcelona, 08041, Spain
  • GSK Investigational Site
    Barcelona, 08950, Spain
  • GSK Investigational Site
    Barcelona, ?08015, Spain
  • GSK Investigational Site
    Barcelona, ?08907, Spain
  • GSK Investigational Site
    Bilbao, 48010, Spain
  • GSK Investigational Site
    Madrid, 28010, Spain
  • GSK Investigational Site
    Madrid, 28034, Spain
  • GSK Investigational Site
    Madrid, 28040, Spain
  • GSK Investigational Site
    Madrid, 28046, Spain
  • GSK Investigational Site
    Sevilla, 41013, Spain
  • GSK Investigational Site
    Birmingham, B4 6DH, United Kingdom
  • GSK Investigational Site
    Brighton, BN2 1ES, United Kingdom
  • GSK Investigational Site
    Edinburgh, EH3 9ES, United Kingdom
  • GSK Investigational Site
    Leeds, LS1 3EX, United Kingdom
  • GSK Investigational Site
    London, E9 6SR, United Kingdom
  • GSK Investigational Site
    London, W2 1NY, United Kingdom
  • GSK Investigational Site
    London, W6 7AL, United Kingdom
  • GSK Investigational Site
    London, WC1E 6JB, United Kingdom
  • GSK Investigational Site
    Manchester, M13 0FH, United Kingdom
  • GSK Investigational Site
    Reading, RG1 5SL, United Kingdom
  • GSK Investigational Site
    St Helens, WA9 3DA, United Kingdom
09

References and documents

Publications

  • Fishman C, Caverly Rae JM, Posobiec LM, Laffan SB, Lerman SA, Pearson N, Janmohamed S, Dumont E, Nunn-Floyd D, Stanislaus DJ. Novel Bacterial Topoisomerase Inhibitor Gepotidacin Demonstrates Absence of Fluoroquinolone-Like Arthropathy in Juvenile Rats. Antimicrob Agents Chemother. 2022 Nov 15;66(11):e0048322. doi: 10.1128/aac.00483-22. Epub 2022 Oct 18. PubMed 36255258 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.gsk.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2019 to primary completion in Oct 2023, 47 months.

Results were first posted in May 2024, 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 2, 2019
First posted
Jul 8, 2019
StartActual
Oct 21, 2019
Primary completionActual
Oct 10, 2023
CompletionActual
Oct 10, 2023
Results first posted
May 30, 2024
Last update
May 30, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 30, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04010539
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jul 8, 2019
Start date
Oct 21, 2019
Primary completion
Oct 10, 2023
Completion
Oct 10, 2023
Results posted
May 30, 2024
Last update
May 30, 2024

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gepotidacin

Start the discussion